Affiliation:
1. From the Medizinische Klinik und Poliklinik, Kardiologie, Charité (Campus Mitte), Humboldt-Universität zu Berlin, Germany. Dr Felix is currently affiliated with the Klinik Innere Medizin B, Universität Greifswald.
Abstract
Background
—We investigated plasma endothelin (ET) levels in patients with congestive heart failure (CHF) during treatment for acute decompensation; we also measured imbalances in ET peptides across the pulmonary, coronary, and peripheral circulation.
Methods and Results
—In patients with severe CHF (n=21; cardiac index [CI], 1.9±0.2 L · min
−1
· m
−2
; pulmonary capillary wedge pressure [PCWP], 31±1 mm Hg), vasodilation was achieved with the nitric oxide donor sodium nitroprusside (n=11) or with the α
1
-antagonist urapidil (nitric oxide–independent, n=10). ET concentrations were determined from arterial blood and blood from the pulmonary artery, coronary sinus, and antecubital vein. Depending on sites of measurement, baseline big ET and ET-1 levels were, respectively, 12 to 16 times and 5 to 11 times higher than in controls (n=11), and 4 to 6 times and 2 to 3 times higher than in patients with moderate CHF (n=10; CI, 2.7±0.3 L · min
−1
· m
−2
; PCWP, 14±2 mm Hg). Patients with severe CHF demonstrated pulmonary net release and coronary and peripheral net consumption of both peptides (ie, arterial levels [big ET, 7.3±1.3 pmol/L; ET-1, 1.8±0.1 pmol/L] were higher than levels in the pulmonary artery [6.7±1.2 pmol/L; 1.3±0.1 pmol/L], coronary sinus [6.4±1.0 pmol/L; 1.4±0.1 pmol/L], and antecubital vein [6.6±1.1 pmol/L; 1.3±0.1 pmol/L]). In these patients, sodium nitroprusside (SNP) and urapidil resulted in comparable hemodynamic improvement after 6 hours (CI: SNP, 63±2%; urapidil, 72±3%; PCWP: SNP, −50±2%; urapidil, −47±2%) and a maximum decrease in ET peptides by >50%. After 3 hours, pulmonary net release and coronary and peripheral net consumption were no longer detectable.
Conclusions
—In patients with severe CHF, the lungs act as a producer and the heart and the periphery act as consumers of elevated circulating ETs. Short-term vasodilator therapy decreases ETs and restores their pulmonary, coronary, and peripheral balance.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Physiology (medical),Cardiology and Cardiovascular Medicine
Cited by
58 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献